Median Survival After Single-ICI, Dual-ICI, TRT, or TRT + Dual-ICI
| Single-ICI | Dual-ICI | TRT + dual-ICI | ||||||
| Control | Anti-CTLA-4 | Anti-PD-L1 | Anti-PD-1 | Anti-PD-L1 + anti-CTLA-4 | Anti-PD-1 + anti-CTLA-4 | TRT (177Lu-LLP2A) | TRT + anti-CTLA-4 + anti-PD-L1 | TRT + anti-CTLA-4 + anti-PD-1 |
| 14 d | 15.5 d | 15.5 d | 15.5 d | 18 d | 17.5 d | 19 d | 23 d | 22 d |
All treatment groups were significantly better than control (P < 0.005). No ICI groups significantly differed except anti-PD-L1 vs. anti-PD-L1 + anti-CTLA-4 (P = 0.0082). TRT + dual-ICI was significantly better than TRT alone (P < 0.001) or dual-ICI (P < 0.0005).